Jump to content

A-77636

From Wikipedia, the free encyclopedia
A-77636
Stereo, Kekulé skeletal formula of A-77636
Names
Preferred IUPAC name
(1R,3S)-3-(Adamantan-1-yl)-1-(aminomethyl)-1H-2-benzopyran-5,6-diol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C20H27NO3/c21-10-17-14-1-2-16(22)19(23)15(14)6-18(24-17)20-7-11-3-12(8-20)5-13(4-11)9-20/h1-2,11-13,17-18,22-23H,3-10,21H2/t11?,12?,13?,17-,18-,20?/m0/s1checkY
    Key: QLJOSZATCBCBDR-DFKUFRTHSA-NcheckY
  • InChI=1/C20H27NO3/c21-10-17-14-1-2-16(22)19(23)15(14)6-18(24-17)20-7-11-3-12(8-20)5-13(4-11)9-20/h1-2,11-13,17-18,22-23H,3-10,21H2/t11?,12?,13?,17-,18-,20?/m0/s1
    Key: QLJOSZATCBCBDR-DFKUFRTHBM
  • Oc1ccc2c(c1O)C[C@H](O[C@H]2CN)C35CC4CC(C3)CC(C4)C5
Properties
C20H27NO3
Molar mass 329.440g·mol−1
Except where otherwise noted, data are given for materials in theirstandard state(at 25 °C [77 °F], 100 kPa).

A-77636is asyntheticdrugwhich acts as aselectiveD1receptorfull agonist.[1]It hasnootropic,anorectic,rewarding andantiparkinsonianeffects in animal studies,[2][3][4][5][6]but its high potency and long duration of action causes D1receptor downregulation andtachyphylaxis,[7][8][9]and unlike other D1full agonists such asSKF-82,958,it does not produce place preference in animals.[10]A-77636 partially substituted forcocainein animal studies, and has been suggested for use as a possible substitute drug in treating addiction,[11]but it is better known for its use in studying the role of D1receptors in the brain.[12][13][14]

References

[edit]
  1. ^Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams M (December 1992). "A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets".European Journal of Pharmacology.229(2–3): 203–9.doi:10.1016/0014-2999(92)90556-J.PMID1362704.
  2. ^Asin KE, Nikkel AL, Wirtshafter D (February 1994). "Repeated D1 receptor agonist treatment blocks cocaine-induced locomotor activity and c-fos expression".Brain Research.637(1–2): 342–4.doi:10.1016/0006-8993(94)91258-0.PMID7910104.S2CID20197207.
  3. ^Ranaldi R, Beninger RJ (July 1994). "The effects of systemic and intracerebral injections of D1 and D2 agonists on brain stimulation reward".Brain Research.651(1–2): 283–92.doi:10.1016/0006-8993(94)90708-0.PMID7922577.S2CID18241791.
  4. ^Grondin R, Bédard PJ, Britton DR, Shiosaki K (August 1997). "Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys".Neurology.49(2): 421–6.doi:10.1212/wnl.49.2.421.PMID9270571.S2CID541898.
  5. ^Cai JX, Arnsten AF (October 1997). "Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys".The Journal of Pharmacology and Experimental Therapeutics.283(1): 183–9.PMID9336323.
  6. ^Cooper SJ, Al-Naser HA, Clifton PG (February 2006). "The anorectic effect of the selective dopamine D1-receptor agonist A-77636 determined by meal pattern analysis in free-feeding rats".European Journal of Pharmacology.532(3): 253–7.doi:10.1016/j.ejphar.2005.11.046.PMID16478622.
  7. ^Lin CW, Bianchi BR, Miller TR, Stashko MA, Wang SS, Curzon P, Bednarz L, Asin KE, Britton DR (March 1996). "Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636".The Journal of Pharmacology and Experimental Therapeutics.276(3): 1022–9.PMID8786531.
  8. ^Saklayen SS, Mabrouk OS, Pehek EA (October 2004). "Negative feedback regulation of nigrostriatal dopamine release: mediation by striatal D1 receptors".The Journal of Pharmacology and Experimental Therapeutics.311(1): 342–8.doi:10.1124/jpet.104.067991.PMID15175419.S2CID36903868.
  9. ^Ryman-Rasmussen JP, Griffith A, Oloff S, Vaidehi N, Brown JT, Goddard WA, Mailman RB (February 2007)."Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors".Neuropharmacology.52(2): 562–75.doi:10.1016/j.neuropharm.2006.08.028.PMC1855220.PMID17067639.
  10. ^Graham DL, Hoppenot R, Hendryx A, Self DW (April 2007). "Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats".Psychopharmacology.191(3): 719–30.doi:10.1007/s00213-006-0473-5.PMID16835769.S2CID21192319.
  11. ^Chausmer AL, Katz JL (January 2002)."Comparison of interactions of D1-like agonists, SKF 81297, SKF 82958 and A-77636, with cocaine: locomotor activity and drug discrimination studies in rodents".Psychopharmacology.159(2): 145–53.doi:10.1007/s002130100896.PMID11862342.S2CID6788631.
  12. ^Acquas E, Wilson C, Fibiger HC (April 1997). "Nonstriatal dopamine D1 receptors regulate striatal acetylcholine release in vivo".The Journal of Pharmacology and Experimental Therapeutics.281(1): 360–8.PMID9103518.
  13. ^Ruskin DN, Rawji SS, Walters JR (July 1998). "Effects of full D1 dopamine receptor agonists on firing rates in the globus pallidus and substantia nigra pars compacta in vivo: tests for D1 receptor selectivity and comparisons to the partial agonist SKF 38393".The Journal of Pharmacology and Experimental Therapeutics.286(1): 272–81.PMID9655869.
  14. ^Bubser M, Fadel JR, Jackson LL, Meador-Woodruff JH, Jing D, Deutch AY (June 2005)."Dopaminergic regulation of orexin neurons"(PDF).The European Journal of Neuroscience.21(11): 2993–3001.doi:10.1111/j.1460-9568.2005.04121.x.hdl:2027.42/71513.PMID15978010.S2CID11527186.


Stub icon

Thisdrugarticle relating to thegastrointestinal systemis astub.You can help Wikipedia byexpanding it.

Stub icon

Thisdrugarticle relating to thenervous systemis astub.You can help Wikipedia byexpanding it.

Stub icon

This article about anorganic compoundis astub.You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=A-77636&oldid=1152079894"